RNAi: A REVOLUTION IN BIOLOGY BUILT ON NOBEL PRIZE-WINNING RESEARCH
RNA interference (RNAi) is a breakthrough in understanding how genes are regulated in cells. It also represents a completely new approach to drug discovery and development. The 2006 Nobel Prize for Physiology or Medicine, awarded to Craig Mello and Andrew Fire, recognised the importance of RNAi as a major scientific discovery.
JOIN OUR TEAM
As we pursue our goal of becoming a commercial organisation that can independently deliver medicines to patients, we are seeking individuals with diverse skills, experiences, and backgrounds to help us build a world-class team. We are based in Cambridge, USA, with offices in Zug, Switzerland, and Maidenhead, UK, but we are also hiring throughout Europe.
CONTACT US
Alnylam UK Ltd.
Braywick Gate, Braywick Road, Maidenhead, Berkshire SL6 1DA
For medical information, clinical trial questions or to report an adverse event or product complaint:
Toll: +44 1628878592
Toll-free: 08001412569 (also hidden caller ID)
Patient Organisation and Public Members Support
View lists of the past UK patient organisations, members of public (including patients and journalists), that Alnylam supported in:
Joint Working Agreements
View the Executive Summaries for Joint Working Agreements with Alnylam UK below:
Live Joint Workings
- National Amyloidosis Centre - hATTR amyloidosis Genetic Counselling and Testing
- National Hospital for Neurology and Neurosurgery and National Amyloidosis Centre
Completed Joint Workings
- National Amyloidosis Centre - hATTR amyloidosis Therapeutic Review - Executive Summary
- National Amyloidosis Centre - hATTR amyloidosis Therapeutic Review - Joint Working Outcomes Summary
- University Hospital Birmingham- Executive Summary
- University Hospital Birmingham- Joint Working Outcomes Summary
UK Disclosure Reports
UK Disclosure Reports are available on the ABPI Disclosure UK website.
The UK Transparency Reporting Methodological Note can be viewed here.
Product Information
For information on Alnylam products, please see:
Reporting of Side Effects
Reporting of side effects: If you have any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme. By reporting side effects, you can help provide more information on the safety of this medicine.
Alnylam UK Ltd.
Date of prep: June 2025
Corp-UK-00083
The following content may not be associated with Alnylam Pharmaceuticals.
Links to all outside sites are provided as a reference for our visitors.
Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.
Proceed to SiteYou are being re-directed to an external website unconnected to Alnylam UK Ltd and the Alnylam group. You are solely responsible for your interactions with that website.
Links to all external sites are provided as a reference for our visitors.
Alnylam UK Ltd and the Alnylam group do not endorse and are not responsible for the content on websites that are not owned and operated by them.
Proceed to SiteYou will be directed to another Alnylam website that may contain information about specific treatment(s), news and more.
Proceed to Site
You will be redirected to an external site that may include social media, event registration, or other third-party content related to Alnylam.
Please note that these external sites have their own terms of service and privacy policies, which may differ from those of Alnylam.
Proceed to Site